Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 12:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 45 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Vesicare Clear all
Completed Phase 4 Interventional Results available

Study of 2 Doses of Solifenacin Succinate in Female Subjects With Overactive Bladder.

NCT01093534
View directory record Official record
Conditions
Detrusor Overactivity, Overactive Bladder
Interventions
Placebo, solifenacin
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older · Female only
Enrollment
547 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
3
States / cities
New York, New York • West Reading, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 3, 2024 · Synced Oct 18, 2026, 12:34 PM EDT
Completed Phase 4 Interventional Results available

A Study to Assess Efficacy and Safety With Solifenacin Succinate to Improve Urinary Continence After Robotic Assisted Radical Prostatectomy

NCT01371994
View directory record Official record
Conditions
Urinary Incontinence
Interventions
solifenacin succinate, Placebo
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older · Male only
Enrollment
640 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
58
States / cities
Homewood, Alabama • Anchorage, Alaska • Tucson, Arizona + 53 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2024 · Synced Oct 18, 2026, 12:34 PM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Solifenacin Succinate Versus Placebo in Inner City Women Ages 20-45 With Overactive Bladder

NCT00773552
View directory record Official record
Conditions
Urinary Urge, Urge Incontinence, Overactive Bladder
Interventions
solifenacin succinate, placebo
Drug
Lead sponsor
Stamford Hospital
Other
Eligibility
20 Years to 45 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
2
States / cities
Stamford, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 6, 2016 · Synced Oct 18, 2026, 12:34 PM EDT
Completed Phase 3 Interventional Results available

Behavioral or Solifenacin Therapy for Urinary Symptoms in Parkinson Disease

NCT03149809
View directory record Official record
Conditions
Overactive Bladder, Parkinson Disease
Interventions
solifenacin, Pelvic floor muscle exercise-based behavioral therapy
Drug · Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
Not listed
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
4
States / cities
Birmingham, Alabama • Decatur, Georgia • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2024 · Synced Oct 18, 2026, 12:34 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Relative Bioavailability Study of Solifenacin Succinate Liquid Suspension (Fed and Fasting) Versus VESIcare Tablet (Fasting) in Healthy Volunteers

NCT01015040
View directory record Official record
Conditions
Bioavailability of Solifenacin Succinate, Pharmacokinetics of Solifenacin Succinate, Healthy Volunteers
Interventions
solifenacin succinate suspension, solifenacin succinate tablet
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 7, 2009 · Synced Oct 18, 2026, 12:34 PM EDT
Withdrawn Phase 4 Interventional

Solifenacin Succinate (VESIcare) for the Treatment of Urinary Incontinence in Parkinson's Disease

NCT00584090
View directory record Official record
Conditions
Urinary Incontinence, Parkinson's Disease
Interventions
Solifenacin Succinate (VESIcare), Placebo
Drug
Lead sponsor
University of South Florida
Other
Eligibility
30 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Dec 3, 2012 · Synced Oct 18, 2026, 12:34 PM EDT
Completed Phase 3 Interventional

Open-label Study of the Efficacy and Safety of VESIcare® in Patients With Overactive Bladder Symptoms

NCT00463541
View directory record Official record
Conditions
Urinary Bladder, Overactive
Interventions
solifenacin succinate
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
2,225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
198
States / cities
Bay Minette, Alabama • Birmingham, Alabama • Decatur, Alabama + 171 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2014 · Synced Oct 18, 2026, 12:34 PM EDT
Completed Phase 3 Interventional Results available

A Study to Investigate How Safe and Effective Solifenacin Solution is in Treating Children/Adolescents With Symptoms of Overactive Bladder (OAB) Who Completed Study 905-CL-076

NCT01655069
View directory record Official record
Conditions
Urinary Bladder, Overactive
Interventions
Solifenacin succinate suspension
Drug
Lead sponsor
Astellas Pharma Europe B.V.
Industry
Eligibility
5 Years to 17 Years
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Shreveport, Louisiana
Source: ClinicalTrials.gov public record
Updated Nov 13, 2024 · Synced Oct 18, 2026, 12:34 PM EDT
Completed Phase 4 Interventional Results available

Validation of a Real-time Urodynamic Measure of Urinary Urgency

NCT00909428
View directory record Official record
Conditions
Overactive Bladder Syndrome
Interventions
Solifenacin Succinate
Drug
Lead sponsor
Loyola University
Other
Eligibility
18 Years and older · Female only
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated May 24, 2017 · Synced Oct 18, 2026, 12:34 PM EDT
Completed Phase 4 Interventional

A Study to Evaluate Solifenacin Succinate in Combination With Tamsulosin for the Treatment of Residual Overactive Bladder Symptoms (OAB) in Men.

NCT00333112
View directory record Official record
Conditions
Urinary Incontinence
Interventions
solifenacin succinate, tamsulosin, placebo
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
45 Years and older · Male only
Enrollment
398 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
74
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tuscon, Arizona + 67 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2014 · Synced Oct 18, 2026, 12:34 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Incontinence & Intimate Partners: Assessing the Contribution of Treatment

NCT01559389
View directory record Official record
Conditions
Urge Urinary Incontinence
Interventions
Solifenacin
Drug
Lead sponsor
Loyola University
Other
Eligibility
18 Years and older
Enrollment
138 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2017
U.S. locations
1
States / cities
Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 2, 2019 · Synced Oct 18, 2026, 12:34 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Medication Effects on Periurethral Sensation,Urethral Sphincter Activity and Pressure Flow Parameters

NCT01028014
View directory record Official record
Conditions
Urethral Sphincter Activity
Interventions
Pseudoephedrine, Tamsulosin, Imipramine, Cyclobenzaprine, Lactose capsule, Solifenacin
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years to 51 Years · Female only
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jun 8, 2012 · Synced Oct 18, 2026, 12:34 PM EDT
Completed Phase 3 Interventional

A Multicenter VESIcare® Efficacy and Safety Study for the Treatment of Urgency Associated With Overactive Bladder (OAB)

NCT00454896
View directory record Official record
Conditions
Urinary Bladder, Overactive
Interventions
VESIcare®, placebo
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
739 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
65
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Atherton, California + 60 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2014 · Synced Oct 18, 2026, 12:34 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Bacterial Genomic Sequencing in Overactive Bladder

NCT01642277
View directory record Official record
Conditions
Overactive Bladder
Interventions
Solifenacin
Drug
Lead sponsor
Loyola University
Other
Eligibility
18 Years to 89 Years · Female only
Enrollment
134 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 7, 2015 · Synced Oct 18, 2026, 12:34 PM EDT
Terminated Phase 3 Interventional Results available

Behavioral Modification and Vesicare Versus Vesicare Alone for Urge Incontinence in Patients With Overactive Bladder

NCT00821184
View directory record Official record
Conditions
Overactive Bladder
Interventions
Vesicare (solifenacin), Vesicare (solifenacin) plus behavioral modification
Drug · Behavioral
Lead sponsor
Lahey Clinic
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Burlington, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 4, 2018 · Synced Oct 18, 2026, 12:34 PM EDT
Completed Phase 4 Interventional Results available

Inflammation in Women With Urgency Urinary Incontinence Treated With Anticholinergics

NCT04090190
View directory record Official record
Conditions
Urinary Incontinence, Urgency Urinary
Interventions
Oxybutynin, Solifenacin, Tolterodine, Trospium, or Fesoterodine
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
50 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 15, 2022 · Synced Oct 18, 2026, 12:34 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

The Effect of Solifenacin on Post Void Dribbling in Women

NCT01470001
View directory record Official record
Conditions
Post-micturition Incontinence, Incontinence
Interventions
solifenacin
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 89 Years · Female only
Enrollment
118 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 23, 2017 · Synced Oct 18, 2026, 12:34 PM EDT
Terminated Not applicable Interventional Results available

Study to Determine Effects of Vesicare on Return to Continence Post- Radical Prostatectomy

NCT00581061
View directory record Official record
Conditions
Incontinence
Interventions
Vesicare
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years to 80 Years · Male only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Oct 7, 2010 · Synced Oct 18, 2026, 12:34 PM EDT
Completed Phase 2 Interventional Results available

A Dose Titration Study of CPC-201 in Patients With Dementia of Alzheimer's Type

NCT02549196
View directory record Official record
Conditions
Dementia of Alzheimer's Type
Interventions
Donepezil, Solifenacin
Drug
Lead sponsor
Chase Pharmaceuticals Corporation, an affiliate of Allergan plc
Industry
Eligibility
50 Years to 89 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
4
States / cities
Deerfield Beach, Florida • Miami, Florida • West Palm Beach, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2019 · Synced Oct 18, 2026, 12:34 PM EDT
Completed Phase 3 Interventional

Efficacy & Safety Study of VESIcare® (Solifenacin Succinate) in Patients Wishing to Switch From Detrol LA® for Treatment of Overactive Bladder

NCT00454740
View directory record Official record
Conditions
Urinary Bladder, Overactive
Interventions
solifenacin succinate
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
441 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
104
States / cities
Anchorage, Alaska • Phoenix, Arizona • Scottsdale, Arizona + 90 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2014 · Synced Oct 18, 2026, 12:34 PM EDT
Completed Phase 4 Interventional Results available

Solifenacin Succinate (VESIcare) for the Treatment of Overactive Bladder in Parkinson's Disease

NCT01018264
View directory record Official record
Conditions
Overactive Bladder in Parkinson's Disease
Interventions
solifenacin succinate (VESIcare), placebo
Drug
Lead sponsor
University of South Florida
Other
Eligibility
40 Years to 80 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
3
States / cities
Miami, Florida • Tampa, Florida • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 9, 2021 · Synced Oct 18, 2026, 12:34 PM EDT
Completed No phase listed Observational

Composur: Study to Understand the Performance of Vibegron in Participants with Overactive Bladder (OAB)

NCT05067478
View directory record Official record
Conditions
Overactive Bladder
Interventions
Vibegron
Drug
Lead sponsor
Urovant Sciences GmbH
Industry
Eligibility
18 Years and older
Enrollment
403 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
64
States / cities
Homewood, Alabama • Phoenix, Arizona • Tempe, Arizona + 54 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2024 · Synced Oct 18, 2026, 12:34 PM EDT
Not listed Phase 4 Interventional

Evaluation of Solifenacin in the Treatment of OAB Symptoms in Patients Who Have Successfully Undergone GreenLight Photoselective Vaporization of the Prostate (PVP)

NCT00826527
View directory record Official record
Conditions
Urinary Frequency, Urinary Urgency, Nocturia
Interventions
Solifenacin PO
Drug
Lead sponsor
Seattle Urology Research Center
Other
Eligibility
18 Years and older · Male only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 22, 2009 · Synced Oct 18, 2026, 12:34 PM EDT
Completed Phase 3 Interventional Results available

A Clinical Study to Investigate How Solifenacin Fluid is Taken up, How Long it Stays in the Body and How Effective and Safe it is in Treating Children Aged From 6 Months to Less Than 5 Years With Symptoms of Neurogenic Detrusor Overactivity (NDO)

NCT01981954
View directory record Official record
Conditions
Neurogenic Detrusor Overactivity, Pediatric
Interventions
Solifenacin succinate
Drug
Lead sponsor
Astellas Pharma Europe B.V.
Industry
Eligibility
6 Months to 4 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Tarrytown, New York
Source: ClinicalTrials.gov public record
Updated Oct 31, 2024 · Synced Oct 18, 2026, 12:34 PM EDT